- COM701 in combination with nivolumab and BMS-986207
(anti-TIGIT) resulted in encouraging confirmed durable partial
responses (overall response rate 22% (2/9) and disease control rate
44%) with a favorable safety profile
- Partial response reported in a patient on study treatment for
almost 7 months who was previously refractory to standard of care
lenvatinib and pembrolizumab
- Greater peripheral immune activation seen in patients
experiencing clinical benefit
- Data further support potential of COM701 in hard-to-treat
tumors including those refractory to immune checkpoint
inhibitors
HOLON, Israel, June 5, 2023
/PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a
clinical-stage cancer immunotherapy company and a pioneer in
computational target discovery, today announced data to be
presented at the American Society of Clinical Oncology (ASCO)
Annual Meeting, showing that Compugen's COM701 (anti-PVRIG) in
triple combination with nivolumab and BMS-986207 (anti-TIGIT)
demonstrated preliminary signal of durable anti-tumor activity in
patients with recurrent, metastatic MSS endometrial cancer with a
favorable safety profile. Preliminary translational data showed an
association between greater peripheral immune activation and
clinical benefit. The poster presentation takes place today,
June 5, 2023.
"Despite recent advances in the standard of care for patients
with recurrent, metastatic MSS endometrial cancer, there remains a
significant need for additional treatment options for these
patients," said Drew W. Rasco, M.D.,
Associate Director of Cancer Research at START Center for Cancer Care, San Antonio, Texas. "It is encouraging to see
preliminary durable anti-tumor activity with a favorable safety
profile in these patients treated with the triple combination of
COM701, nivolumab and BMS-986207. Importantly, one-third of the
patients included had prior exposure to an anti-PD-(L)1 making
these a particularly hard to treat patient population with a
significant unmet medical need. A patient with prior treatment
refractory disease to standard of care lenvatinib and
pembrolizumab, experienced a partial response and remained on
treatment with triple combination for almost 7 months pointing to
the potential contribution of blocking PVRIG and TIGIT to the
benefit seen. It is also noteworthy that clinical benefit, defined
as a partial response or stable disease greater than 100 days,
correlated with peripheral immune activation as shown by the
translational data to be presented."
Henry Adewoye, MD., Chief Medical
Officer of Compugen, added, "I am delighted to see the preliminary
data we have reported, including a confirmed partial response in a
patient with endometrial carcinosarcoma, a rare hard-to-treat
histologic type of endometrial cancer that is not typically
responsive to standard of care therapies. The translational
findings in patients with clinical benefit are also in line with
the mechanistic rationale of the combination. Although the number
of patients enrolled is small, these data and the clinical signal
reported support our hypothesis of blocking the DNAM-1 axis with
anti-PVRIG, TIGIT and PD-1 antibodies. This preliminary data
complements previous data we presented in patients with
hard-to-treat platinum resistant ovarian cancer and metastatic
microsatellite stable colorectal cancer. It supports a COM701
mediated mechanism of action and further development of this triple
immunotherapy combination as another potential option in treating
cancer."
The abstract is published on the ASCO virtual platform and the
publication section of Compugen's website. The poster will be
available today from 1:15pm CDT on
the publication section of Compugen's website.
About Compugen
Compugen is a clinical-stage therapeutic discovery and
development company utilizing its broadly applicable predictive
computational discovery capabilities to identify new drug targets
and biological pathways for developing cancer
immunotherapies. Compugen has developed two proprietary
product candidates: COM701, a potential first-in-class anti-PVRIG
antibody and COM902, a potential best-in-class antibody
targeting TIGIT for the treatment of solid tumors. Compugen also
has a clinical stage partnered program, rilvegostomig (previously
AZD2936), a PD-1/TIGIT bi-specific derived from COM902, in Phase 2
development by AstraZeneca through a license agreement for the
development of bi-specific and multi-specific antibodies. In
addition, the Company's therapeutic pipeline of
early-stage immuno-oncology programs consists of programs
aiming to address various mechanisms of immune resistance. The most
advanced program, COM503 is in IND enabling studies. COM503 is
a potential first-in-class, high affinity antibody which blocks the
interaction between IL-18 binding protein and IL-18, thereby
freeing natural IL-18 to inhibit cancer growth in the tumor
microenvironment. Compugen is headquartered in Israel, with offices in San Francisco, CA. Compugen's shares
are listed on Nasdaq and the Tel Aviv Stock Exchange under the
ticker symbol CGEN.
Forward-Looking Statement
This press release contains "forward-looking statements" within
the meaning of the Securities Act of 1933 and the Securities
Exchange Act of 1934, as amended, and the safe-harbor provisions of
the Private Securities Litigation Reform Act of 1995. Such
forward-looking statements are based on the current beliefs,
expectations, and assumptions of Compugen. Forward-looking
statements can be identified using terminology such as "will,"
"may," "expects," "anticipates," "believes," "potential," "plan,"
"goal," "estimate," "likely," "should," "confident," and "intends,"
and similar expressions that are intended to identify
forward-looking statements, although not all forward-looking
statements contain these identifying words. Forward-looking
statements include, but are not limited to, statements regarding
the potential contribution of blocking PVRIG and TIGIT to the
benefit seen. These forward-looking statements involve known and
unknown risks and uncertainties that may cause the actual results,
performance, or achievements of Compugen to be materially different
from any future results, performance or achievements expressed or
implied by such forward-looking statements. Among these risks: In
the near term, Compugen is highly dependent on the success of
COM701 and of COM902; Compugen may not be able to advance its
internal clinical stage programs through clinical development or
manufacturing or successfully partner or commercialize them, or
obtain marketing approval, either alone or with a collaborator, or
may experience significant delays in doing so; Clinical development
involves a lengthy and expensive process, with an uncertain outcome
and Compugen may encounter substantial delays or even an inability
to begin clinical trials for any specific product or may not be
able to conduct or complete its trials on the timelines it expects;
Compugen has limited experience in the development of therapeutic
product candidates, and it may be unable to implement its business
strategy. These risks and other risks are more fully discussed in
the "Risk Factors" section of Compugen's most recent Annual Report
on Form 20-F as filed with the Securities and Exchange Commission
(SEC) as well as other documents that may be subsequently filed by
Compugen from time to time with the SEC. In addition, any
forward-looking statements represent Compugen's views only as of
the date of this release and should not be relied upon as
representing its views as of any subsequent date. Compugen does not
assume any obligation to update any forward-looking statements
unless required by law.
Company contact:
Yvonne Naughton, Ph.D.
Head of Investor Relations and Corporate Communications
Email: ir@cgen.com
Tel: +1 (628) 241-0071
View original
content:https://www.prnewswire.com/news-releases/compugens-com701-anti-pvrig-demonstrates-preliminary-durable-anti-tumor-activity-in-triple-immunotherapy-combination-in-patients-with-recurrent-metastatic-mss-endometrial-cancer-301842192.html
SOURCE Compugen Ltd.
